Clinical trials: Metastases, CNS
Neoplasm Metastasis, Lung Neoplasms
Characterization of Brain Metastases
The purpose is to characterize tumour biological markers in brain metastases tissue from patients with different primary tumour by using ex vivo techniques as high-resolution magic angle spinning MR spectroscopy and micro array.
- Conditions
- Neoplasm Metastasis, Lung Neoplasms, Breast Neoplasms, Melanoma
- Trial name
- NCT00184275
- Where
- Norway
- Volunteers
- 26 people
- Sponsor
- Norwegian University of Science and Technology
Brain and Central Nervous System Tumors, Metastatic Cancer
Temozolomide in Treating Patients With Primary Brain Tumors or Metastatic Brain Tumors
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00547131
- Testing
- temozolomide, laboratory biomarker analysis, liquid chromatography
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- City of Hope Medical Center
Brain Neoplasms
Magnetic Resonance Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors
In this study, the Visualase Thermal Therapy System will be used on metastatic brain tumors that cannot be removed by surgery. Researchers want to find out if it is possible to use this new device in subjects with 1-3 metastatic…
- Trial name
- NCT00787982
- Testing
- MRI-Guided Laser Induced Thermal Therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Visualase, Inc.
Neoplasm Metastasis
Cognitive Outcome After SRS or WBRT in Patients With Multiple Brain Metastases (CAR-Study B)
Whole Brain Radiation Therapy (WBRT) has long been the mainstay of treatment for patients with multiple brain metastases (BM). Meanwhile, Gamma Knife radiosurgery (GKRS) has been increasingly employed in the management of…
- Trial name
- NCT02953717
- Testing
- Gamma Knife radiosurgery, Whole Brain Radiation Therapy
- Where
- Netherlands
- Volunteers
- 81 people
- Sponsor
- Elisabeth-TweeSteden Ziekenhuis
Multiple Sclerosis (MS), Relapsing-remitting Multiple Sclerosis (RRMS)
Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis
This project is to: 1. Quantify differences in axonal integrity and organization in aMS versus naPMS patients. 2. Quantify changes in axonal integrity and organization in aMS versus naPMS patients over a two-year period. 3.
- Conditions
- Multiple Sclerosis (MS), Relapsing-remitting Multiple Sclerosis (RRMS), Secondary-progressive Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS)
- Trial name
- INsIDER (NCT05177523)
- Testing
- MRI, Neurocognitive examination for healthy subjects, blood sampling
- Where
- Switzerland
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Atherosclerosis, Ischemia
Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)
This study is designed to evaluate the long-term ocular safety of SCH 530348 (vorapaxar) in participants with established atherosclerotic disease who are enrolled into the TRA 2°P - TIMI 50 Study (P04737) (NCT00526474).
- Conditions
- Atherosclerosis, Ischemia, Myocardial Infarction, Cerebrovascular Accident
- Trial name
- NCT00617123
- Testing
- Vorapaxar 2.5 mg
- Volunteers
- 258 people
- Sponsor
- Merck Sharp & Dohme LLC
NSCLC Stage IV, Brain Metastases
Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis
Non-small cell lung cancer (NSCLC), the most prevalent form of lung cancer, has a significant risk of brain metastasis (BM). Historically, the median overall survival for advanced NSCLC patients with BM was under six months with…
- Trial name
- NCT06501391
- Testing
- PD-L1/PD-1 inhibitor and chemotherapy, SRT or WBRT
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Fudan University
Pirtobrutinib, Sintilimab
Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma
This is a prospective, single-Arm, phase II clinical study evaluating the efficacy and safety of thiotepa in combination with pirtobrutinib (a BTK Inhibitor) and sintilimab (a PD-1 Inhibitor) for frail or relapsed/refractory…
- Conditions
- Pirtobrutinib, Sintilimab, Central Nervous System Lymphoma
- Trial name
- NCT07416890
- Testing
- Thiotepa, Pirtobrutinib , Sintilimab(TPS)
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Zhejiang Cancer Hospital
Transient Ischemic Attack, Non-disabling Stroke
Prevention of Ischemic Conditions in Non-disabling Stroke/Transient Ischemic Attack With Remote Ischemic Conditioning
This is a single-arm, open-labeled and phase II futility study. Application of Remote ischemic conditioning (RIC) as an adjunctive therapy to medication were involved in the study.
- Trial name
- PICNIC-ONE (NCT03004820)
- Testing
- Remote Ischemic Conditioning
- Where
- 4 sites in China
- Volunteers
- 167 people
- Sponsor
- Capital Medical University
Lymphoma Cns
A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA）
Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX intolerance) or Temozolomide (TMZ) Combined with Orelabrutinib and Selinexor in the Treatment of Relapsed/Refractory Primary or Secondary…
- Trial name
- SELINA (NCT07191431)
- Testing
- Selinexor+Orelabrutinib+Methotrexate/Thiotepa/Temozolomide
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Ruijin Hospital
Post-Dural Puncture Headache, Sphenopalatine Ganglion Block
Effectiveness of Sphenopalatine Ganglion Block for Post-Dural Puncture Headache
The objective of the study is to determine the effectiveness of Spheno-Palatine (SP) ganglion block to alleviate the pain of post-dural puncture headache (PDPH).
- Trial name
- NCT03430531
- Testing
- Lidocaine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Milton S. Hershey Medical Center
Brain Metastases
Tomotherapy as Primary Radiotherapy for Multipule Brain Metastases
This clinical trial was designed to investigate the efficiency and toxicity of tomotherapy as primary radiotherapy for multiple brain metastases.
- Trial name
- NCT04178330
- Testing
- tomotherapy
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Chinese Academy of Medical Sciences
Brain Cancer, Brain Cancer Metastatic
PilotStudyAssessSafeActiveSurveillancApproachLocalThe Pa w/BrainMetsUndergoinCNSPenetratSystemicThe
This is a Pilot clinical trial determining the safety of an active surveillance approach to local therapy in subjects with brain metastases. These are subjects who are undergoing CNS-penetrating systemic therapy.
- Conditions
- Brain Cancer, Brain Cancer Metastatic, Nervous System Cancer, CNS Cancer
- Trial name
- NCT07827001
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, Irvine
Metastatic Colon Cancer
Detection of Brain Metastasis by MRI in Metastatic Colorectal Cancer Patients
The aim of this study is to prospectively determine the incidence of brain metastases in metastatic colorectal cancer patients using systematic annual screening by MRI.
- Trial name
- NCT03694938
- Testing
- Magnetic resonance imaging
- Where
- 4 sites in France
- Volunteers
- 143 people
- Sponsor
- Poitiers University Hospital
Lung Carcinoma Metastatic to the Brain
MRI Perfusion on T1 and T2 Brain Lesion(s)
This study therefore aims to assess current treatment recommended by scientific societies [ 6-13 ] , brain MRI with injection of contrast for the diagnosis and monitoring of brain metastases .
- Trial name
- METAPERF (NCT02250755)
- Testing
- MRI T1 T2 sequences
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Lille
Brain and Central Nervous System Tumors, Leukemia
Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial
RATIONALE: Gathering information about why patients or their guardians agree or decline to participate in the optional pharmacokinetic portion of a phase I treatment study may help doctors plan clinical trials in the future.
- Conditions
- Brain and Central Nervous System Tumors, Leukemia, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00890435
- Testing
- questionnaire administration, psychosocial assessment and care
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Children's Oncology Group
Stroke
Effectiveness of Self-monitoring and Treatment of Blood Pressure Following Stroke or Transient Ischaemic Attack
This blinded end point RCT will recruit high risk TIA and mild stroke patients (through the emergency TIA clinics and the acute stroke services at the Norfolk \& Norwich University Hospital) who require anti-hypertensive therapy…
- Trial name
- TEST-BP (NCT02947490)
- Testing
- Self BP measurement, Standard Care, Standard BP management
- Where
- United Kingdom
- Volunteers
- 165 people
- Sponsor
- University of East Anglia
Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis
The purpose of this study is to compare the safety and efficacy of masitinib 6 mg/kg/day versus placebo in the treatment of patients with primary progressive multiple sclerosis or relapse-free secondary progressive multiple…
- Conditions
- Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Relapse Free
- Trial name
- NCT01433497
- Testing
- Masitinib
- Where
- 8 sites in Bulgaria, France and 5 more
- Volunteers
- 656 people
- Sponsor
- AB Science
Leptomeningeal Metastasis, Solid Tumor, Adult
177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)
Adults with leptomeningeal metastasis from solid tumors will be treated with 177Lu-DTPA-omburtamab, which is a radioactive labelling of a murine monoclonal antibody targeting B7-H3.
- Trial name
- NCT04315246
- Testing
- radiolabeled DPTA-omburtamab
- Where
- 8 sites in United States, United Kingdom
- Sponsor
- Y-mAbs Therapeutics
Central Nervous System Lymphoma
Selinexor in Combination With MTX+Ritu to Treat R/R CNSL
This is a single-arm and open-label study to explore X+MTX+Ritu (ATG-010, Methotrexate, Rituximab) regimen in Relapse refractory PCNSL patients. Approximately 30 patients will be enrolled in the study.
- Trial name
- NCT05698147
- Testing
- Selinexor, Rituximab, Methotrexate
- Where
- 5 sites in China
- Volunteers
- 30 people
- Sponsor
- Tong Chen, MD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.